TLSA Key Statistics, Chart & Performance
The current stock price of TLSA is 1.79 USD. In the past month the price decreased by -6.77%. In the past year, price increased by 77.23%.
TLSA Latest News, Press Relases and Analysis
TLSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About TLSA
Company Profile
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Company Info
TIZIANA LIFE SCIENCES LTD
3rd Floor, 11-12 St. James's Square
London SW1Y 4LB GB
CEO: Kunwar Shailubhai
Employees: 9
Phone: 442074952379
TIZIANA LIFE SCIENCES LTD / TLSA FAQ
What does TLSA do?
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
What is the stock price of TIZIANA LIFE SCIENCES LTD today?
The current stock price of TLSA is 1.79 USD. The price decreased by -0.56% in the last trading session.
Does TLSA stock pay dividends?
TLSA does not pay a dividend.
How is the ChartMill rating for TIZIANA LIFE SCIENCES LTD?
TLSA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting TLSA stock to perform?
7 analysts have analysed TLSA and the average price target is 8.16 USD. This implies a price increase of 355.87% is expected in the next year compared to the current price of 1.79.
Can you provide the number of employees for TIZIANA LIFE SCIENCES LTD?
TIZIANA LIFE SCIENCES LTD (TLSA) currently has 9 employees.
What is the ownership structure of TIZIANA LIFE SCIENCES LTD (TLSA)?
You can find the ownership structure of TIZIANA LIFE SCIENCES LTD (TLSA) on the Ownership tab.
TLSA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to TLSA. When comparing the yearly performance of all stocks, TLSA is one of the better performing stocks in the market, outperforming 92.63% of all stocks.
TLSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TLSA. While TLSA seems to be doing ok healthwise, there are quite some concerns on its profitability.
TLSA Financial Highlights
Over the last trailing twelve months TLSA reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 14.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.37% | ||
| ROE | -139.58% | ||
| Debt/Equity | 0 |
TLSA Forecast & Estimates
7 analysts have analysed TLSA and the average price target is 8.16 USD. This implies a price increase of 355.87% is expected in the next year compared to the current price of 1.79.